Rx Bandz, LLC was notified on March 12, 2020, that the US Air Force has awarded Rx Bandz a contract to conduct further research and development to adapt Rx Bandz’s novel auto-injector “MiniJect™” to protect military personnel. Financial terms of the agreement were not disclosed, but it will provide upfront funding for development to meet Air Force tactical needs.
Jessica Walsh, Rx Bandz CEO, and founder said, “We are honored and thrilled to be given this opportunity to protect those who put their lives on the line for all of us. Warfighters are more often in advance or isolated situations where they have to administer medications themselves or for others. MiniJect™ unique features will provide a superior solution for emergency situations.”
The company’s MiniJect™ can be used to deliver a wide range of injectable medications. It is well-suited to combat situations as it is rugged, easy to carry, intuitive to use in adverse conditions and is waterproof. The device is designed to be robust in environments from deserts to alpine theaters of war.
Rx Bandz is advanced in its development to obtain FDA approval for its first commercial application of MiniJect™ for the delivery of epinephrine to people at risk for anaphylactic shock due to severe food and insect bite allergies.
Funding for this development comes partially from the Small Business Innovation Research program (SBIR) working in coordination with the Air Force. The Small Business Innovation Research program is seeding the future of the U.S. Air Force through innovation and forward-thinking technology, bringing novel solutions to the battlefield.